Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.
暂无分享,去创建一个
S. Meijer | P. Kenemans | J. Vermorken | S. Litvinov | G. Kamp | G. V. van Kamp | A. Verstraeten | J. Hilgers | M. Gourevitch | S. von Mensdorff‐Pouilly | S. Mensdorff-Pouilly | Sybren L. Meijer
[1] P. Kenemans,et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. , 1995, British Journal of Cancer.
[2] M. Reddish,et al. Does pregnancy immunize against breast cancer? , 1995, Cancer research.
[3] J. Fagerberg,et al. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] J. Fagerberg,et al. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. , 1995, Cancer research.
[5] F. Hanisch,et al. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells. , 1995, European journal of biochemistry.
[6] A. Sonnenberg,et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.
[7] J. Banchereau,et al. Recent advances in the study of dendritic cells and follicular dendritic cells. , 1995, Immunology today.
[8] J. Devitt. Breast cancer: have we missed the forest because of the tree? , 1994, The Lancet.
[9] M. Gross,et al. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. , 1994, Cancer research.
[10] A. Epenetos,et al. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer , 1994, Cancer.
[11] R. Metzgar,et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.
[12] G. Riethmüller,et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.
[13] N. Tjandra,et al. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. , 1993, Cancer research.
[14] L. Frati,et al. Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients. , 1993, In vivo.
[15] S. Litvinov,et al. The epithelial sialomucin, episialin, is sialylated during recycling. , 1993, The Journal of biological chemistry.
[16] T. Irimura,et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. , 1993, Journal of immunology.
[17] M. Kieny,et al. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[18] K. Jerome,et al. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. , 1993, Journal of immunology.
[19] C. Melief,et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. , 1993, Journal of immunology.
[20] L. Frati,et al. Human B-cell immune response to the polymorphic epithelial mucin. , 1993, Cancer research.
[21] F. Itoh,et al. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. , 1993, Immunology letters.
[22] M. Ligtenberg,et al. Cell membrane-associated mucins and their adhesion-modulating property. , 1992, Trends in biochemical sciences.
[23] T. Duhig,et al. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. , 1992, Development.
[24] R. Bast,et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.
[25] N. Peat,et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.
[26] R. W. Baldwin,et al. Immunological and structural features of the protein core of human polymorphic epithelial mucin. , 1990, Molecular immunology.
[27] M. Ligtenberg,et al. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. , 1990, The Journal of biological chemistry.
[28] I. Mckenzie,et al. Glycosylation and the exposure of tumor-associated epitopes on mucins , 1990 .
[29] M. Lan,et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Ligtenberg,et al. Complexity of MAM-6, an epithelial sialomucin associated with carcinomas. , 1989, Cancer research.
[31] C. Melief. Dendritic cells as specialized antigen-presenting cells. , 1989, Research in immunology.
[32] M. Larché,et al. DEVELOPMENT OF ANTI-IDIOTYPIC ANTIBODIES AGAINST TUMOUR ANTIGENS AND AUTOANTIGENS IN OVARIAN CANCER PATIENTS TREATED INTRAPERITONEALLY WITH MOUSE MONOCLONAL ANTIBODIES , 1988, The Lancet.
[33] S. Zotter. Tissue and tumor distribution of human polymorphic epithelial mucin , 1988 .
[34] J. Taylor‐Papadimitriou,et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. , 1987, Cancer research.
[35] V. Zurawski,et al. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] P. Bruning,et al. MAM-6 antigen, a new serum marker for breast cancer monitoring. , 1986, Cancer research.
[37] D. Hayes,et al. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. , 1985, The Journal of clinical investigation.
[38] A. Sonnenberg,et al. Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumors , 1984, International journal of cancer.
[39] J. Schlom,et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. , 1984, Hybridoma.
[40] W. Bodmer,et al. Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.